Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 3;118(10):e2024852118. doi: 10.1073/pnas.2024852118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

PMC Copyright notice

Fig. 4. — Effect of dexamethasone and LTA4H rs17525495 genotype on survival probability of patients from Tobin et al. (8) and Thuong et al. (7). Mean posterior survival probability curves; inset plots represent mean posterior hazard rates for the first 30 d. Shaded areas represent the 95% Bayesian confidence limits for posterior probability. (A) In Tobin et al. (8) (No Dex), TT survival was nonsignificantly reduced compared to non-TT (maximum probability 0.946). (B) In Tobin et al. (8) (Dex), TT survival was significantly greater than non-TT from day 40 onwards (maximum probability 0.976, survival gap 17%). Probability that TT hazard rate (Inset) is lower than non-TT is >0.95 from day 2 to day 252 (maximum probability 0.972, peak ratio 7.5 at day 97). CT survival was significantly greater than CC from day 3 onwards (maximum probability 0.999, survival gap 23%), and CT hazard rate significantly lower than CC from day 1 onwards (maximum probability 0.996, ratio peaks at 12 on day 3 and remains >3 throughout). (C) In Thuong et al. (7) patients (Dex), CC and CT survival comparisons do not differ significantly (maximum probability 0.91). TT survival was significantly greater than CC from day 42 onwards (maximum probability 0.987, survival gap 12%). Probability that TT hazard rate is lower than CC is >0.95 days 15 to 138 (maximum probability 0.991, ratio peaks at 3.4 on day 62 and remains >1 until day 250). TT survival was also significantly greater than CT from day 53 to day 254 (maximum probability 0.964, survival gap 9%). Probability that TT hazard rate is lower than CT is >0.95 from day 7 to day 73 (maximum probability 0.979, ratio peaks at 2.9 on day 22 and remains >1 to day 234). (D) In CC (+Dex) patients, survival was nonsignificantly greater in the Thuong et al. (7) cohort (maximum probability 0.939, survival gap 9%). (E) In CT (+Dex) patients, survival was significantly greater in the Tobin et al. (8) cohort from day 5 onwards (maximum probability 0.993, survival gap 11%). Tobin CT (+Dex) hazard rate was significantly lower than Thuong CT from day 2 to day 45 (maximum probability 0.997, peak ratio 9.8 on day 4). (F) In TT patients (+Dex), survival was nonsignificantly greater in the Tobin et al. (8) cohort (maximum probability 0.90, survival gap 6%). (G) Tobin CC patient survival did not differ significantly with and without Dex treatment (maximum probability 0.80). (H) Tobin CT patient survival was significantly greater with Dex from day 7 to day 88 (maximum probability 0.964, survival gap 11%). CT (+Dex) hazard rate was significantly lower than CT (No Dex) from day 3 to day 18 (maximum probability 0.967, peak ratio 9 on day 2 and remains >1 throughout). (I) Tobin TT patient survival was significantly greater with Dex from day 1 onwards (maximum probability 0.997, survival gap 41%). TT (+Dex) hazard rate was significantly lower from day 1 onwards (maximum probability 0.996, peak ratio 35 on day 2). See SI Appendix, Supplementary Box S2 for explanation of definitions and abbreviations used.